The CFO of Advaxis (NASDAQ: ADXS) is Selling Shares

By Carrie Williams

Yesterday, the CFO of Advaxis (NASDAQ: ADXS), Sara Bonstein, sold shares of ADXS for $12.74K.

In addition to Sara Bonstein, 3 other ADXS executives reported Sell trades in the last month.

The company has a one-year high of $10.88 and a one-year low of $3.04. Currently, Advaxis has an average volume of 497.3K.

The insider sentiment on Advaxis has been negative according to 50 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Advaxis, Inc. is a clinical-stage biotechnology company, which intends to develop immunotherapies for cancer and infectious diseases. The company’s platform technology is designed to generate a comprehensive immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor. Advaxis was founded on June 5, 1987 and is headquartered in Princeton, NJ.